18 Participants Needed

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

(BUTTER Trial)

JB
AG
Overseen ByAlexis Griggs, BA
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing tributyrin, a substance that turns into a helpful fatty acid in the body. It aims to see if it can improve brain function and metabolism in people with Parkinson's disease and normal older adults. If successful, it could lead to further studies on using this fatty acid for health benefits. Sodium butyrate, a similar compound to tributyrin, has shown potential in improving motor and cognitive deficits in Parkinson's disease models.

Do I need to stop my current medications for the trial?

The trial excludes people who regularly use anti-cholinergic, benzodiazepines, or neuroleptic drugs, so you may need to stop these medications to participate. The protocol does not specify about other medications.

What makes the drug Tributyrin unique compared to other treatments?

Tributyrin is unique because it is a triglyceride that can be metabolized into butyrate, a short-chain fatty acid that has potential anti-inflammatory and anticancer properties. This makes it different from other treatments that may not provide the same metabolic benefits or target similar pathways.12345

Who Is on the Research Team?

NI

Nicolaas I Bohnen, MD, PhD

Principal Investigator

University of Michigan

Are You a Good Fit for This Trial?

Inclusion Criteria

Healthy control volunteers over 45 years of age
People with Parkinson Disease over 45 years of age

Exclusion Criteria

Evidence of large vessel stroke or mass lesion on MRI
Poorly controlled diabetes
Dementia requiring informed assent
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 500mg TID tributyrin supplement for 30 days +/- 7 days

4-5 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Tributyrin
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Parkinson's Disease Tributyrin InterventionExperimental Treatment1 Intervention
Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Group II: Healthy Control Tributyrin InterventionExperimental Treatment1 Intervention
Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Nicolaas Bohnen, MD, PhD

Lead Sponsor

Trials
2
Recruited
50+

Citations

Identification of (S)-11-cycloheptyl-4-methylundecanoic acid in acylphosphatidylglycerol from Alicyclobacillus acidoterrestris. [2009]
Lipid diversity in clostridia. [2022]
Predicting glycerophosphoinositol identities in lipidomic datasets using VaLID (Visualization and Phospholipid Identification)--an online bioinformatic search engine. [2021]
Novel lipids of Butyrivibrio spp. [2019]
Profiling of lipid species by normal-phase liquid chromatography, nanoelectrospray ionization, and ion trap-orbitrap mass spectrometry. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security